BiotechTube

Rabeprazole or Esomeprazole or Lanzoprazole

Pre-clinicalCompleted
0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Calcium Metabolism Disorders

Conditions

Calcium Metabolism Disorders

Trial Timeline

Oct 1, 2009 → Jul 1, 2010

NCT ID
NCT01139645

About Rabeprazole or Esomeprazole or Lanzoprazole

Rabeprazole or Esomeprazole or Lanzoprazole is a pre-clinical stage product being developed by AstraZeneca for Calcium Metabolism Disorders. The current trial status is completed. This product is registered under clinical trial identifier NCT01139645. Target conditions include Calcium Metabolism Disorders.

Hype Score Breakdown

Clinical
3
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01139645Pre-clinicalCompleted

Competing Products

1 competing product in Calcium Metabolism Disorders

See all competitors
ProductCompanyStageHype Score
Lumasiran + PlaceboAlnylam PharmaceuticalsPhase 2
24